<DOC>
	<DOCNO>NCT01714115</DOCNO>
	<brief_summary>This single patient investigative treatment study . The patient diagnose retinal tumor one eye . In last 2 year , patient treat available conventional therapy , include intraocular injection Avastin Lucentis , steroid , photodynamic therapy . Any positive result short-term , cause eventual decline central vision . Aflibercept show effective growth new vessel , secondary macular degeneration . This study propose may also effective treat particular patient case . The study treatment plan 6 month initially , intention continue treatment .</brief_summary>
	<brief_title>Use Eylea Treatment Optic Nerve Hemangioma</brief_title>
	<detailed_description>The treatment plan administer aflibercept 2.0 mg intravitreally every two four week least six consecutive injection . Prior initiation therapy study visit , full ophthalmic examination , best-corrected visual acuity , complete review system monitor toxicity perform . In addition , investigator perform fluorescein indocyanine green angiography baseline obtain color fundus photograph well spectral domain OCT image properly document extent degree activity vascular tumor baseline study visit .</detailed_description>
	<mesh_term>Hemangioma</mesh_term>
	<criteria>retinal hemangioma previously treat conventional therapy , include Avastin , Lucentis , steroid , photodynamic therapy , less ideal result ongoing reevaluation adverse event , include inflammation , elevate intraocular pressure , suspect toxicity aflibercept</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>